{"url_path":"/sec/pdsb/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-025121-index.html","accession_number":"0001140361-26-025121","cik":"0001472091","ticker":"PDSB","issuer_name":"PDS Biotechnology Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-025121-index.html","primary_entity_key":"0001472091","primary_entity_name":"PDS Biotechnology Corp"},"word_count":246,"has_tables":true,"body_markdown":"Item 8.01.\n\nOther Events.\n\nThe board of directors (the “Board”) of PDS Biotechnology Corporation (the “Company”) has scheduled the Company’s 2026 Annual\nMeeting of Stockholders (the “2026 Annual Meeting”) for August 10, 2026. More detailed information regarding the 2026 Annual Meeting will be set forth in the Company’s Definitive Proxy Statement on Schedule 14A to be filed with the Securities and\nExchange Commission (“SEC”).\n\nBecause the date of the 2026 Annual Meeting is more than 30 days from the anniversary date of the Company’s 2025 Annual Meeting\nof Stockholders (the “2025 Annual Meeting”), the Company has set a deadline of June 25, 2026 for the submission of stockholder proposals pursuant to Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for inclusion in\nthe Company’s proxy materials for the 2026 Annual Meeting. Proposals of stockholders must also comply with SEC rules regarding the inclusion of stockholder proposals in proxy materials and the Company may omit from its proxy materials any proposal\nthat does not comply with the SEC’s rules. Proposals should be sent to PDS Biotechnology Corporation, 303A College Road East, Princeton, New Jersey 08540, Attention: Corporate Secretary.\n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on\nits behalf by the undersigned hereunto duly authorized.\n\n \n\nPDS BIOTECHNOLOGY CORPORATION\n\n \n\n \n\nDate: June 15, 2026\n\nBy:\n\n/s/ Frank Bedu-Addo, Ph.D.\n\n \n\nName: Frank Bedu-Addo, Ph.D.\n\n \n\nTitle: President and Chief Executive Officer"}